Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
Introduction. Cardiovascular diseases are the leading cause of death worldwide. The combination of statins and cholesterol-absorption inhibitors promotes the decrease in risk factors, such as high concentrations of LDL (low-density lipoproteins). The aim of the study was to evaluate changes in the l...
Saved in:
Main Authors: | Joel Rodríguez-Saldaña, Francisco Padilla-Padilla, Ernesto G. Cardona-Muñoz, Yulia Romero-Antonio, María Marcela Arguedas-Núñez, José G. Sander-Padilla, Alberto Martínez-Muñoz, Laura A. Lugo-Sánchez, Ileana C. Rodríguez-Vazquez, Jorge González-Canudas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Cardiology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2022/9464733 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ezetimibe Improves Rosuvastatin Effects on Inflammation and Vascular Endothelial Function in Acute Coronary Syndrome Patients Undergoing PCI
by: Changqing Sun, et al.
Published: (2021-01-01) -
Spectrophotometric Determination of Ezetimibe
by: P. Baby Sudha Lakshmi, et al.
Published: (2010-01-01) -
Ezetimibe: An Unusual Suspect in Angioedema
by: Tiffany Lu, et al.
Published: (2020-01-01) -
Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives
by: Akshyaya Pradhan, et al.
Published: (2020-01-01) -
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
by: Vavlukis Ana, et al.
Published: (2023-09-01)